Latest Financials News

Xamble Group has acquired a 19% stake in Malaysia’s leading loyalty platform B Infinite, aiming to deepen influencer marketing engagement and unlock new revenue streams across Southeast Asia.

European Lithium Ltd and Critical Metals Corp have updated the Tanbreez Rare Earth Project scoping study, incorporating feldspar and arfvedsonite alongside eudialyte, underpinning a robust $2.4–3.0 billion NPV and a 162% IRR over a 19-year mine life.

European Lithium has announced a significant addendum to its Tanbreez Project Mineral Resource Estimate, adding 180 million tonnes of feldspar and arfvedsonite to the existing rare earth elements resource base. This broadens the project's economic scope and underlines its potential as a world-class rare earth development.

Mayfield Childcare Limited reports a significant operational and financial turnaround in Q2 FY25 under new CEO Daniel Stone, with improved earnings and cost efficiencies despite ongoing sector pressures.

Select Harvests Limited reported a robust half-year FY2025 profit, driven by a 37.6% jump in almond prices and strategic debt refinancing. Despite a slightly reduced crop volume, the company’s outlook remains positive amid strong global demand.

Careteq Limited faces a significant repayment demand from the ATO over R&D tax claims but is mounting a formal objection backed by legal counsel.

Select Harvests Limited has reported a remarkable turnaround with a $28.7 million profit in the first half of FY2025, buoyed by higher almond prices and improved operational efficiency. The company also secured $240 million in refinancing, positioning itself for future growth despite a slightly reduced almond crop forecast.

Select Harvests Limited has reported a remarkable turnaround with a $28.7 million net profit for the half-year ended March 2025, driven by higher almond prices and operational gains. The company forecasts a solid 2025 crop and has renewed a $240 million syndicated debt facility.

Aroa Biosurgery has reported FY25 results that exceed revenue guidance and deliver a positive normalised EBITDA, setting the stage for ambitious growth and reimbursement expansion in FY26.

Aroa Biosurgery has reported a robust 23% revenue increase in FY25, achieving profitability and positive cash flow, setting the stage for continued growth in FY26.

Noxopharm has secured ethics approval to commence the HERACLES trial, marking the first human study of its novel SOF-SKN™ drug aimed at chronic inflammatory diseases.

Metrics Master Income Trust (ASX:MXT) has launched a fully underwritten wholesale placement to raise up to A$315 million, aiming to fund portfolio growth and diversification. The placement, priced at A$2.00 per unit, will see new units issued and trading commence in early June 2025.